Clinical and pharmacological review on novel melatonergic antidepressant: Agomelatine

Research Journal of Pharmaceutical, Biological and Chemical Sciences

Volumn 1, Issue 2, 2010, Pages 446-450

  Venkat Rao, P ^a   Prabhakar, T ^a   Naveen, Ch R ^a   Ramakrishna, S ^a   Trinath, G ^a  

^a ANDHRA UNIVERSITY   (India)

Author keywords

Jgomelatine; Major depressive disorder (MDD)

Indexed keywords

AGOMELATINE; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELITOR; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CLINICAL PHARMACOLOGY; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; EVENING DOSAGE; HUMAN; MAJOR DEPRESSION; NAUSEA; NONHUMAN; SEX DIFFERENCE; SINGLE DRUG DOSE; SLEEP INDUCTION; TISSUE DISTRIBUTION;

EID: 79952581025     PISSN: None     EISSN: 09758585     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Dan J Stein, Antti A Ahokas, Christian de Bodinat. J Clin Psychopharmacol 2008.
2. H Lôo, A Hale, H D'haenen. Int J Clin Psychopharmacol 2002.
3. www.agomelatin.com.
4. H Lôo, J Daléry, J P Macher, A Payen. Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin- agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders L'Encéphale. 2003 Mar-Apr.
5. http://www.ecplaza.net/tradeleads/seller/6223638/agomelatinecasno138112762.html.